<img alt="Vasiprak FNB Pvt Ltd" data-src="https://www.vasiprakfnb.com/wp-content/uploads/2021/08/Vasiprak-logo-2.svg" class="logo-dark lazyload" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw=="><noscript><img src="https://www.vasiprakfnb.com/wp-content/uploads/2021/08/Vasiprak-logo-2.svg" alt="Vasiprak FNB Pvt Ltd" class="logo-dark" >

<img alt="Vasiprak FNB Pvt Ltd" data-src="https://www.vasiprakfnb.com/wp-content/uploads/2021/08/Vasiprak-logo-White-2.svg" class="logo-light lazyload" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw=="><noscript><img src="https://www.vasiprakfnb.com/wp-content/uploads/2021/08/Vasiprak-logo-White-2.svg" alt="Vasiprak FNB Pvt Ltd" class="logo-light" >

Vasiprak FNB Pvt Ltd

Breaking Boundaries since 2018

Vasiprak Blog

medicare

Roche executive says Alzheimer’s drug price will be competitive, Health News, ET HealthWorld

By Deena Beasley Roche Holding AG, still months away from seeking regulatory approval of its experimental Alzheimer’s drug, is already taking aim at rival Biogen Inc’s Aduhelm, saying that its…

Biogen trial of ALS drug fails main goal, but company says data are encouraging, Health News, ET HealthWorld

By Deena Beasley A late-stage trial of Biogen Inc’s experimental treatment for an inherited form of amyotrophic lateral sclerosis (ALS) failed to reach its main goal, but secondary measures and…